TES10

Tesamorelin (also known as TH9507 ) is a synthetic 44-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH). It is a stabilized version of the natural GHRH produced by the hypothalamus.

How It Works

Tesamorelin binds to GHRH receptors on the anterior pituitary gland, stimulating the pulsatile release of endogenous growth hormone (GH). This leads to increased production of Insulin-like Growth Factor-1 (IGF-1) in the liver.

Key downstream effects include:

• Lipolysis (fat breakdown), particularly targeting visceral adipose tissue (deep abdominal fat around organs).
• Improved body composition: reduction in fat mass with preservation or slight increase in lean muscle mass.
• Metabolic benefits: potential improvements in lipid profiles (e.g., lower triglycerides and cholesterol).
• It mimics the body’s natural regulatory feedback systems more closely than direct GH administration, leading to more physiologic pulses rather than constant elevation.

Approved Uses and Potential Benefits

Tesamorelin is FDA-approved (since 2010) specifically for the reduction of excess abdominal (visceral) fat in HIV-infected adult patients with lipodystrophy. Clinical trials showed significant reductions in visceral adipose tissue (VAT), improved body image, and some metabolic benefits.

In research, fitness, bodybuilding, and anti-aging contexts, people explore it off-label for:

• Targeted visceral fat loss (stubborn belly fat that is metabolically harmful).
• Improved body composition — fat reduction while supporting lean mass.
• Metabolic health — better lipid profiles, potential insulin sensitivity support (though monitoring is required).
• Anti-aging and recovery — increased GH/IGF-1 can aid muscle recovery, skin quality, energy, and overall vitality.

It is often preferred over direct GH because it encourages the body’s own production in a more natural pattern.

Important Caveats

• FDA-approved indication is narrow: Only for HIV-associated lipodystrophy. Off-label use (e.g., general fat loss or anti-aging) is common in peptide communities but not formally approved and requires medical supervision.
• Potential side effects: Injection-site reactions, joint/muscle pain (arthralgia, myalgia), swelling/fluid retention (edema), carpal tunnel-like symptoms, and increased risk of glucose intolerance or diabetes. It may worsen existing malignancies or be contraindicated in certain conditions (e.g., active cancer, pregnancy).
• Monitoring required: Regular checks of IGF-1 levels, blood glucose, and other parameters are important.
• Regulatory note for research peptides: While the pharmaceutical version is approved, compounded or research-grade versions vary in quality and purity.

Bottom line: Tesamorelin is one of the best-studied peptides for safely elevating natural GH levels and specifically targeting harmful visceral fat. It stands out for its FDA approval in its primary indication and more physiologic action compared to direct GH. For your EDB LLC peptide products, highlight the research context, strong disclaimers, and the importance of consulting a healthcare professional. As with all peptides in your lineup (BPC-157, TB-500, IGF-1 LR3, etc.), emphasize quality sourcing and legal/medical guidance.